Nephron Patent-Cliff Exposure & CMS Drug Spending Portfolio

Nephron (US): 2 reconciled FDA prescription therapies, $55.9M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies2
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$55.9M
2024 Medicare Part D Spend$18.3M
2024 Medicaid Spend$37.6M
California HCAI SB 17 Filings0 statutory filings in 2023 to 2026 panel